accepted the hospitality of a leading producer of drugs. The Committee utilised the Government machinery provided by Commissioner, FDCA Gujarat.

(b) and (c) In view of reply at (a), do not arise.

Retention of certain drugs under D.P.C.O.

1587. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry received representations in regard to the inclusion of Oxyphedrine, Hydrochloride, Nandrolone Phenyl Propionat and Nandrolone from Consumer Associations and Members of Parliament for consideration by Kelkar Committee;

(b) if so, when were such representations sent to Kelkar Committee;

(c) whether it is a fact that none of these drugs fulfil any exclusion criteria laid down Kelkar Committee;

(d) whether it is also a fact that Kelkar Committee has not referred about these drugs in the supplementary report; and

(e) what are the reasons for non-consideration of two representations and on what grounds the same have been retained under price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The recommendations of the Kelkar Committee regarding inclusion of certain drugs under DPCO, 1987 contained in their Supplementary Report are yet to be examined by the Government.

Representation for inclusion of certain drugs in DPCO

1588. SHRI DHARNIDHAR BASUMATARI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee received representations for inclusion of Diphenhydramine Hcl, Noscapine, Methdilazine Hcl, Triprolidine and Thioridazins Hcl, under price control after the term of committee was extended for removal of discrepancies;

(b) if so, how many representations in respect to these drugs were received and what are the details thereof;

(c) whether it is a fact that Kelkar Committee has not made any indication in respect to these drugs;

(d) whether it is also a fact that these drugs do not fulfil any exclusion criteria and

(e) if so, what steps have been taken to examine these representations and rectify the position?

THE MINISTER OF INDUSTRY (SHRI J. VENGALRAO): (a) to (e) The recommendations of the Kelkar Committee regarding inclusion of certain drugs under DPCO, 1987 contained in their Supplementary Report are yet to be examined by the Government.

Price Control on Testosterone Medicines

1589. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee as well as his Ministry received representations for removal of anomalies and discrepencies for inclusion of Testosterone, Allyloestraneol, droxyprogestrone Caproate and Ethinyl Estrodiol;

(b) if so, number of representations received and what are the details and grounds on which each submission was made;

(c) whether it is a fact that Kelkar Committee has not dealt with these representations for inclusion of these drugs in the supplementary report;